• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.

    5/15/25 1:14:39 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care
    Get the next $PAVM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    PAVmed Inc.

    (Name of Issuer)


    Common Stock, Par Value $0.001 Per Share

    (Title of Class of Securities)


    70387R403

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    70387R403


    1Names of Reporting Persons

    FIRST MANHATTAN CO. LLC.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    700,000.00
    6Shared Voting Power

    14,100.00
    7Sole Dispositive Power

    700,000.00
    8Shared Dispositive Power

    14,100.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    714,100.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PAVmed Inc.
    (b)Address of issuer's principal executive offices:

    360 MADISON AVENUE, 25TH FLOOR, NEW YORK, NEW YORK, 10017.
    Item 2. 
    (a)Name of person filing:

    First Manhattan Co. LLC
    (b)Address or principal business office or, if none, residence:

    399 Park Avenue New York, NY 10022
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock, Par Value $0.001 Per Share
    (e)CUSIP No.:

    70387R403
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    714,100
    (b)Percent of class:

    4.25%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    700,000

     (ii) Shared power to vote or to direct the vote:

    14,100

     (iii) Sole power to dispose or to direct the disposition of:

    700,000

     (iv) Shared power to dispose or to direct the disposition of:

    14,100

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FIRST MANHATTAN CO. LLC.
     
    Signature:Jeremy Covino
    Name/Title:Chief Compliance Officer
    Date:05/15/2025
    Get the next $PAVM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PAVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      11/14/24 10:02:46 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      9/23/24 8:46:15 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      2/14/24 3:38:38 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Tasso Partners, Llc claimed ownership of 2,574,350 shares (SEC Form 3)

      3 - PAVmed Inc. (0001624326) (Issuer)

      3/14/25 7:53:09 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Agrawal Sundeep

      4 - PAVmed Inc. (0001624326) (Issuer)

      10/23/24 4:36:47 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Agrawal Sundeep

      4 - PAVmed Inc. (0001624326) (Issuer)

      9/20/24 4:13:39 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

      Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15th, at 8:30 AM EDT NEW YORK, May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical

      5/15/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

      Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25 Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Conference call and webcast to be held today, May 14th, at 8:30 AM EDT NEW YORK, May 14, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended March 31, 2025.

      5/14/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on PAVmed with a new price target

      Cantor Fitzgerald initiated coverage of PAVmed with a rating of Overweight and set a new price target of $8.00

      3/30/21 6:22:24 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lake Street Capital reiterated coverage on PAVmed with a new price target

      Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously

      2/22/21 4:33:18 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Financials

    Live finance-specific insights

    See more
    • PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

      Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15th, at 8:30 AM EDT NEW YORK, May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical

      5/15/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Leadership Updates

    Live Leadership Updates

    See more
    • PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

      Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements.  As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain

      9/16/24 4:30:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

      Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing

      5/7/24 7:39:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

      The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO NEW YORK, March 21, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has launched a wholly owned incubator, PMX, to complete development and commercialization of existing portfolio technologies, including the PortIO™ Implantable Intraosseous Vascular Access Device ("PortIO"), EsoCure™ Esophageal Ablation Device ("EsoCure"), and CarpX® Minimally Inva

      3/21/24 8:30:00 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.

      SCHEDULE 13G/A - PAVmed Inc. (0001624326) (Subject)

      5/15/25 1:14:39 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PAVmed Inc. (0001624326) (Filer)

      5/15/25 8:25:38 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by PAVmed Inc.

      10-Q - PAVmed Inc. (0001624326) (Filer)

      5/14/25 9:32:50 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care